Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alcoholism
New research on alcoholism from Queen's University summarized
May 11th, 2008
"Although acetaminophen overdose is a leading cause of fulminant hepatic failure, it is controversial whether therapeutic doses of acetaminophen can cause hepatotoxicity in alcoholics, especially those rendered most vulnerable by recent abstinence. We performed a randomized, triple-blind, parallel-group trial comparing sustained-release acetaminophen, 1300mg orally q8h for 11 doses, against placebo," researchers in Kingston, Canada report. "We enrolled chronic alcohol abusers (defined as >= 6 drinks daily for >= 6 weeks) who had discontinued alcohol consumption 12 to 72 hours prior to enrolment. Individuals with self-reported viral hepatitis, HIV or intravenous...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-11)
|
